Caris Life Sciences (CAI) executive receives 63,971-share restricted stock grant

Rhea-AI Filing Summary

Power Luke Thomas reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences, Inc. executive Luke Thomas Power received an equity grant in the form of restricted stock units. The award covers 63,971 shares of Common Stock, granted at no cash cost to him as compensation. According to the footnote, these restricted stock units will vest in line with the terms of the applicable grant agreement. Following this grant, he directly holds 163,542 shares of Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Power Luke Thomas

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	63,971	$0.00	--

Holdings After Transaction: Common Stock — 163,542 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Power Luke Thomas

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TX 75039

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A		63,971(1)	A	$0	163,542	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Remarks:

Senior Vice President, Chief Financial Officer, and Chief Accounting Officer

	/s/ J. Russel Denton, Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Caris Life Sciences (CAI) report for Luke Thomas Power?

Caris Life Sciences reported that executive Luke Thomas Power received a grant of 63,971 restricted stock units of Common Stock. The award is compensation-based, carries no purchase price, and increases his direct holdings to 163,542 shares following the transaction.

Was the Caris Life Sciences (CAI) Form 4 transaction a stock purchase or a grant?

The Form 4 transaction was a grant of restricted stock units, not an open-market stock purchase. The 63,971 units were awarded as compensation, with no cash price per share, and will vest according to the terms of the related grant agreement.

How many Caris Life Sciences (CAI) shares does Luke Thomas Power hold after this Form 4?

After the reported grant, Luke Thomas Power directly holds 163,542 shares of Caris Life Sciences Common Stock. This total includes the newly awarded 63,971 restricted stock units, which vest over time under the conditions set out in the applicable grant agreement.

What does the footnote about the Caris Life Sciences (CAI) restricted stock units explain?

The footnote explains that the 63,971 reported shares represent an award of restricted stock units. These units do not vest immediately; instead, they vest in accordance with the schedule and conditions specified in the applicable grant agreement between the company and the executive.

Does the Caris Life Sciences (CAI) Form 4 indicate any stock sales by Luke Thomas Power?

The Form 4 does not report any stock sales by Luke Thomas Power. It only shows an acquisition via a grant of 63,971 restricted stock units, increasing his direct Common Stock holdings to 163,542 shares after this compensation-related award.